Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0,47%
1 067,36
+4,96
+0,47%
—1 062,401 064,141 071,991 061,02——
SIXC
Communications
SIXC
Communications
SIXC
-0,54%
603,48
-3,26
-0,54%
—606,74606,74609,84602,33——
SIXE
Energy
SIXE
Energy
SIXE
+0,54%
1 244,93
+6,72
+0,54%
—1 238,211 236,601 247,741 232,10——
SIXI
Industrials
SIXI
Industrials
SIXI
+0,68%
1 730,38
+11,77
+0,68%
—1 718,611 723,231 741,481 717,47——
SIXM
Financials
SIXM
Financials
SIXM
+0,33%
639,47
+2,10
+0,33%
—637,37638,27642,30638,27——
SIXR
Staples
SIXR
Staples
SIXR
+0,16%
854,95
+1,36
+0,16%
—853,59854,05858,19851,34——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0,11%
218,56
+0,23
+0,11%
—218,33218,33219,73217,15——
SIXT
Technology
SIXT
Technology
SIXT
+1,02%
3 631,59
+36,78
+1,02%
—3 594,813 620,103 657,473 615,34——
SIXU
Utilities
SIXU
Utilities
SIXU
+0,80%
915,77
+7,23
+0,80%
—908,54909,50917,35907,07——
SIXV
Health care
SIXV
Health care
SIXV
+1,19%
1 512,81
+17,81
+1,19%
—1 495,001 499,611 517,101 499,61——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,41%
2 408,21
+9,90
+0,41%
—2 398,312 406,822 421,802 404,22——
BOT:ASX
Botanix Pharmaceuticals Ltd
0,025 AUD
+4,17%
(+0,0010) 1D
22-май, 16:10:06 GMT+10  ·   AUD
All symbols
SymbolPriceChange% Change
Generating top insights for BOT...
Open
0,02 AUD
High
0,03 AUD
Low
0,02 AUD
Mkt. cap
81,72 млн
Avg. vol.
28,44 млн
Volume
38,22 млн
52-wk high
0,40 AUD
52-wk low
0,02 AUD
EPS
-0,05 AUD
Shares outstanding
2,72 млд
No. of employees
11
News stories
From sources across the web
Profile
Botanix Pharmaceuticals is listed on the Australian Securities Exchange with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic cannabinoid company, focusing on the compound Cannabidiol. The company's lead product is Sofdra, which treats axillary hyperhidrosis. The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex, for direct skin delivery of active pharmaceuticals which is utilised in all of their programs. Wikipedia
About Botanix Pharmaceuticals Ltd
CEO-
Employees11
Founded1984
Headquarters-
SectorPharmaceutical industry
Websitebotanixpharma.com
Last report
2026-ж., 27-янв.
Fiscal period
Q2 2026
EPS / Est. (AUD)
- / -
Revenue / Est. (AUD)
8,25 млн / -
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in AUD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in AUD
2025-ж. мар.
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
Revenue
2,71 млн
2,71 млн
8,25 млн
8,25 млн
Cost of goods sold
1,28 млн
1,28 млн
2,98 млн
2,98 млн
Cost of revenue
1,28 млн
1,28 млн
2,98 млн
2,98 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
21,36 млн
21,36 млн
18,32 млн
18,32 млн
Operating expense
26,90 млн
26,90 млн
22,08 млн
22,08 млн
Total operating expenses
28,18 млн
28,18 млн
25,06 млн
25,06 млн
Operating income
-25,47 млн
-25,47 млн
-16,81 млн
-16,81 млн
Other non operating income
-
-
683,30 миң
683,30 миң
EBT including unusual items
-27,75 млн
-27,75 млн
-16,60 млн
-16,60 млн
EBT excluding unusual items
-27,75 млн
-27,75 млн
-16,60 млн
-16,60 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-27,75 млн
-27,75 млн
-16,60 млн
-16,60 млн
Net profit margin
-1 025,73%
-1 025,73%
-201,11%
-201,11%
Earnings per share
-
-
-
-
Interest and investment income
347,27 миң
347,27 миң
352,66 миң
352,66 миң
Interest expense
-2,67 млн
-2,67 млн
-802,39 миң
-802,39 миң
Net interest expenses
-2,32 млн
-2,32 млн
-449,74 миң
-449,74 миң
Depreciation and amortization charges
572,87 миң
572,87 миң
593,18 миң
593,18 миң
EBITDA
-24,90 млн
-24,90 млн
-16,22 млн
-16,22 млн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer